http://www.businessweek.com/investor/content/feb2003/pi2003025_1660_pi010.htmBoston Scientific (BSX ): Reiterates 5 STARS (buy) Analyst: Robert Gold The company posted fourth quarter results in line with recent guidance, with sales up 19% before an $11 million currency benefit, and operating earnings per share of 31 cents vs. 20 cents. Boston Scientific notes that January results met their plan, with some upside in urology. The European launch of its drug-coated stent is expected by mid-February. S&P still anticipates a premarketing approval (PMA) filing in the U.S. in June, with the release of Taxus IV data in September and a launch in the early fourth quarter. S&P continues to see 2003 earnings per share at $1.30, and 2004 at $2.50. Estimated S&P Core earnings per share of 89 cents in 2002 is seen rising by 31% to $1.17 in 2003.
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimate